PPARγ Agonist Beyond Glucose Lowering Effect
نویسندگان
چکیده
منابع مشابه
PPARγ Agonist Beyond Glucose Lowering Effect
The nuclear hormone receptor PPARγ is activated by several agonists, including members of the thiazolidinedione group of insulin sensitizers. Pleiotropic beneficial effects of these agonists, independent of their blood glucose-lowering effects, have recently been demonstrated in the vasculature. PPARγ agonists have been shown to lower blood pressure in animals and humans, perhaps by suppressing...
متن کاملGlucose-lowering effect of DLBS3233 is mediated through phosphorylation of tyrosine and upregulation of PPARγ and GLUT4 expression
BACKGROUND DLBS3233 is a standardized extract combination containing Lagerstroemia speciosa and Cinnamomum burmannii. The effect of DLBS3233 on glucose uptake, adiponectin secretion, and insulin signaling was examined in this study. METHODS 3T3 Swiss albino preadipocytes and adipocytes were used to investigate gene expression detected using the reverse transcription polymerase chain reaction ...
متن کاملSodium-Glucose Cotransporter 2 Inhibitors: Possible Anti-Atherosclerotic Effects Beyond Glucose Lowering
The new drug for type 2 diabetes, the sodium-glucose cotransporter 2 (SGLT-2) inhibitor, is reversible inhibitor of SGLT-2, leading to reduction of renal glucose reabsorption and decrease of plasma glucose, in an insulin-independent manner. In addition to glucose control, the management of coronary risk factors is very important for patients with diabetes. Here we reviewed published articles ab...
متن کاملModulation by the PPARγ Agonist Rosiglitazone
Early after stroke onset, ischemic injury is exacerbated by a robust inflammatory response that involves a local reaction as well as an influx of blood-borne cells recruited by cytokines, adhesion molecules, and chemokines. Among these cells, neutrophils are rapidly mobilized from the bone marrow to provide an effective innate immune response; they rapidly infiltrate into the ischemic brain (a ...
متن کاملTolerance Does Not Develop Toward Liraglutide's Glucose-Lowering Effect.
Context Glucagon-like peptide-1 receptor agonists are popular antidiabetic drugs with potent glucose-lowering effects and low risk of hypoglycemia. Animal experiments and human data indicate that tolerance develops toward at least some of their effects (e.g., gastric motility). Whether tolerance develops toward the glucose-lowering effect of glucagon-like peptide-1 receptor agonists has never b...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Korean Journal of Internal Medicine
سال: 2011
ISSN: 1226-3303
DOI: 10.3904/kjim.2011.26.1.19